Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GABA Combination vs Ginger for Vertigo-kinetosis
NCT05221892Phase 4
Key facts
- Status
- Completed
- Start
- Nov 2021
- Primary completion
- Mar 2023
- Countries
- 1
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands, Metabolically Activated Prodrugs
01
Overview
Phase 4, randomised, double-blind trial of gamma-aminobutyric acid tartarate + glutamic acid + dibasic calcium phosphate + thiamine nitrate + pyridoxine chloride + cyanocobalamin, Glutamic acid, dicalcium phosphate, thiamine nitrate, pyridoxine and 1 more in vertigo and motion sickness (2 arms), sponsored by Fundação Educacional Serra dos Órgãos. Primary endpoint: Motion Sickness Assessment Questionnaire score at 1 year. Started Nov 2021; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Test combination
GABA + Glutamic Acid + Calcium + B1 + B6 + B12
Comparative medication
Ginger extract
03
Who it enrols
Adult patients with clinical kinetosis, excluding those with gallbladder stones, gastric mucosa inflammation, or uncontrolled hypertension.
04
Endpoints
Primary
Motion Sickness Assessment Questionnaire score
Beyond the preview
Go deeper on NCT05221892.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05221892.